Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Asaf Danziger
|
| gptkbp:clinicalTrialPhase |
EF-14
|
| gptkbp:countryOfOrigin |
gptkb:Israel
|
| gptkbp:FDAApproved |
Optune for glioblastoma
|
| gptkbp:focus |
gptkb:cancer
|
| gptkbp:founded |
2000
|
| gptkbp:founder |
gptkb:Yoram_Palti
|
| gptkbp:headquartersLocation |
gptkb:Saint_Helier,_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novocure
|
| gptkbp:industry |
medical device
|
| gptkbp:numberOfEmployees |
over 1,000
|
| gptkbp:product |
Optune
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
gptkb:glioblastoma
mesothelioma |
| gptkbp:S&P500Component |
false
|
| gptkbp:stockSymbol |
NVCR
|
| gptkbp:subsidiary |
Novocure GmbH
|
| gptkbp:technology |
Tumor Treating Fields
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.novocure.com/
|
| gptkbp:bfsParent |
gptkb:Zai_Lab
gptkb:tumor-treating_fields |
| gptkbp:bfsLayer |
7
|